Circuit Reaffirms Invalidity of Pfizer's Norvasc Patent

Law360, New York (June 5, 2007, 12:00 AM EDT) -- A circuit court on Tuesday reaffirmed that a Pfizer Inc. patent for popular hypertension drug Norvasc is invalid by overturning a patent infringement ruling against Mylan Laboratories Inc.

The U.S. Court of Appeals for the Federal Circuit reversed a district court ruling that a launch of generic Norvasc, known as amlodine besylate, would infringe the Pfizer patent. District Judge Terrence F. McVerry of the U.S. District Court for the Western District of Pennsylvania had ruled in February that Pfizer's patent covering amlodine besylate was valid, enforceable...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.